Acquisition of Van Heek Medical

Asker Healthcare Group has agreed to acquire 100% of Allion B.V. (Van Heek Medical), a Benelux-focused manufacturer and distributor of diabetes management, incontinence and wound-care products serving homecare, pharmacies and nursing homes; Van Heek reported roughly SEK 350 million in revenue last year and has 64 employees. The deal, subject to regulatory and customary approvals, is expected to close in Q1 2026 and to be accretive to Asker’s EBITA margin. The acquisition strengthens Asker’s Benelux footprint and product portfolio as the SEK 16 billion-revenue group (about 4,500 employees) pursues scale and margin improvement across European healthcare markets.

Analysis

Asker Healthcare Group has signed an agreement to acquire 100% of Allion B.V. (Van Heek Medical), a Benelux-focused manufacturer and distributor of diabetes management, incontinence and wound-care products that serves homecare, pharmacies and nursing homes. Van Heek reported approximately SEK 350 million of revenue in the past financial year and employs 64 people, indicating a compact, regionally concentrated business model.

Management frames the deal as a targeted expansion of Asker’s Benelux footprint and product portfolio; CEO Johan Falk cited Van Heek’s well‑established customer relationships and complementary offerings. Asker is a much larger platform (approximately SEK 16 billion revenue and more than 4,500 employees across 19 countries), so the acquisition is strategic rather than transformational in scale.

The transaction remains subject to regulatory and customary approvals and is expected to complete in Q1 2026 and to contribute positively to Group EBITA margin, implying anticipated accretion if approvals and integration proceed as planned. Market signals are mildly positive with limited immediate market impact, so regulatory timing and execution/integration risk are the primary near-term uncertainties to monitor.

Key Decisions for Investors

• Monitor the regulatory approval timeline and any conditions tied to a Q1 2026 close, as delays or remedies would affect the expected EBITA accretion
• Reassess Asker’s margin and consolidation models to quantify the impact of an additional SEK 350 million in revenue and consider selectively increasing exposure if management provides clear post-close guidance or synergy metrics
• Maintain a measured position until integration milestones and customer retention in the Benelux market are demonstrated, focusing on execution risk rather than headline strategic rationale